ERBB2 and breast cancer: The study identified 792,581 female patients age ≥50 years with a diagnosis of clinical T1-4c, N0-1, ER+/HER2– breast cancer from 2012 to 2021 who met all the other inclusion and exclusion criteria (Fig. 1).